Search

EHA at ICH meeting: Excessive bureaucracy harms patient safety and innovation

To solicit input from a wide range of non-ICH members about the revision of ICH E8(R1), ICH held a Public Meeting on ICH E8(R1) “General Considerations for Clinical Studies” (Silver Spring, USA, October 31, 2019).

Read more

Meet Antonio Almeida, our February Volunteer of the Month

EHA is a Public Benefit Organization under Dutch law.

Read more

Meet Antonio Almeida, our February Volunteer of the Month

EHA is a Public Benefit Organization under Dutch law.

Read more

“Nothing about us without us”: how patient advocacy is changing the game

Nuno Borges MBBS MRes, on behalf of YoungEHA
When it comes to advancing medical care, there is no denying that patients are at the core of everything we do.

Read more

EHA-LSHBT Virtual Hematology Updates, a Successful Course Tailored for the Region!

March – October 2021

In a series of six webinar courses chairs Gianluca Gaidano (EHA) and Ali Taher (LSHBT) were joined by several experts that gave lectures and interactive patient cases to practitioners who manage patients with benign and hematologic malignancies.…

Read more

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more